Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir

S.m. Bester, Daniel Adu‐Ampratwum, Arun S. Annamalai, Guochao Wei, Lorenzo Briganti, Bridget C. Murphy, Reed Haney, James R. Fuchs, Mamuka KvaratskheliamBio 2022 · DOI

TL;DR

This study investigates how HIV-1 develops resistance to the potent capsid inhibitor lenacapavir (LEN). By determining the high-resolution structures of resistant HIV-1 capsid variants, researchers identified specific amino acid changes (Q67H and N74D) that disrupt LEN binding through conformational shifts and electrostatic repulsions. These insights were used to design a modified lenacapavir analog with improved potency against resistant strains, paving the way for next-generation HIV-1 inhibitors with higher resistance barriers.

What Problem Does This Paper Address?

Lenacapavir (LEN) is a promising long-acting HIV-1 capsid (CA) inhibitor showing significant potential for treating HIV-1 infection. However, a key challenge is the relatively low barrier to viral resistance, meaning HIV-1 can evolve mutations that make it less susceptible to the drug. Identifying these "resistance-associated mutations" (RAMs) and understanding the underlying structural and mechanistic reasons for this resistance is crucial for developing more robust and durable antiviral therapies. This paper specifically addresses the resistance conferred by the Q67H and N74D mutations in the HIV-1 capsid, which have been observed in both laboratory studies and clinical trials.

Methods

The researchers employed a multi-pronged approach combining structural biology, biophysical characterization, and medicinal chemistry.

  • X-ray Crystallography: High-resolution (up to 2.15 Å) crystal structures of HIV-1 capsid (CA) hexamers were determined. This included structures of wild-type (WT) CA, CA with individual resistance mutations (Q67H, N74D), and CA with the combined mutation (Q67H/N74D), both in the absence and presence of lenacapavir (LEN). This allowed for detailed visualization of how the mutations affect the binding site.
  • Surface Plasmon Resonance (SPR): SPR was used to quantitatively measure the binding kinetics (association and dissociation rates) and affinity (K<sub>D</sub>) of LEN to both WT and mutant CA hexamers. This provided biophysical data to complement the structural insights.
  • Medicinal Chemistry and Rational Drug Design: Based on the structural and mechanistic understanding of resistance, the researchers rationally modified LEN to create a new analog (KFA-012). This involved altering specific parts of the LEN molecule predicted to be affected by the resistance mutations.
  • Antiviral Assays: The antiviral activity of both LEN and the new analog (KFA-012) was tested against various HIV-1 strains, including WT and those with the identified resistance mutations, using cell culture-based assays.

Datasets

Not explicitly discussed as "datasets" in the traditional machine learning sense. The primary data sources are:

  • Structural Data: High-resolution X-ray crystal structures of HIV-1 CA hexamers (WT and mutant variants) in complex with LEN, deposited in the Protein Data Bank (PDB) under accession codes 7RAR, 7RMM, 7RHM, 7RHN, 7RJ4, 7RJ2, and 7RMJ.
  • Biophysical Data: Surface Plasmon Resonance (SPR) data detailing binding kinetics and affinities (K<sub>D</sub>, k<sub>on</sub>, k<sub>off</sub>) for LEN with different CA variants.
  • Antiviral Activity Data: EC<sub>50</sub> values from cell culture assays measuring the potency of LEN and KFA-012 against various HIV-1 strains.

Key Insights and Ideas

  • Conformational Switch for Resistance: The Q67H mutation forces the histidine side chain at position 67 to adopt a "closed" conformation in the absence of LEN, which sterically hinders LEN binding. Upon LEN binding, it must switch to an "open" conformation, similar to the wild-type glutamine, to accommodate the drug. This conformational flexibility requirement is proposed to be the primary driver of reduced potency against Q67H.
  • Electrostatic Repulsion and Loss of Hydrogen Bond: The N74D mutation disrupts a crucial hydrogen bond between the wild-type Asn74 and LEN. Furthermore, the change to aspartate introduces a more negative charge to the binding site, leading to electrostatic repulsion with the negatively charged sulfonamide group of LEN, further reducing binding affinity.
  • Cumulative Effects of Mutations: The double Q67H/N74D mutation exhibits amplified resistance effects, combining the conformational challenges of Q67H with the electrostatic repulsions and loss of hydrogen bonding from N74D. This leads to a significantly higher fold-change in resistance compared to either single mutation.
  • Targeted Drug Modification: The structural insights directly informed the design of a new LEN analog (KFA-012). By modifying the cyclopenta-pyrazole ring of LEN to a more flexible tetrahydroindazole ring, the researchers aimed to reduce the steric clash caused by the Q67H mutation.
  • Proof-of-Concept for Next-Generation Inhibitors: The development of KFA-012, which shows improved potency against resistant strains, serves as a proof-of-concept for rationally designing next-generation CA inhibitors with enhanced resistance barriers.

Key Results

  • Binding Affinity Reduction:
    • Q67H mutation reduced LEN binding affinity (K<sub>D</sub>) by approximately 5-fold, primarily due to a reduced dissociation rate (k<sub>off</sub>).
  • N74D mutation reduced LEN binding affinity by approximately 20-fold, affecting both association (k<sub>on</sub>) and dissociation (k<sub>off</sub>) rates.
  • The Q67H/N74D double mutation reduced LEN binding affinity by approximately 150-fold.
  • Structural Basis for Resistance: High-resolution crystal structures revealed the specific interactions and conformational changes underlying resistance:
  • Q67H: His67 side chain adopts a sterically hindering "closed" conformation in the absence of LEN, requiring a switch to an "open" conformation for binding.
  • N74D: Loss of a direct hydrogen bond between Asn74 and LEN, and introduction of electrostatic repulsion due to increased negative charge.
  • Improved Analog Potency: The modified LEN analog, KFA-012, showed:
  • Approximately 1.8-fold and 2.6-fold higher potency against HIV-1 with Q67H and Q67H/N74D mutations, respectively, compared to LEN.
  • Slightly better activity against WT and N74D CA variants.
  • SPR analysis indicated a ~2-fold improved binding affinity of KFA-012 to CA(Q67H/N74D) hexamers compared to LEN.
  • Selectivity: KFA-012 demonstrated a high selectivity index (>10,000) in cytotoxicity assays.

Limitations and Future Work

  • Modest Improvement for KFA-012: While KFA-012 shows improved potency against Q67H/N74D variants, the viruses remain largely resistant to it. The improvements are described as "relatively modest."
  • Further Resistance Emergence: The paper notes that other resistance mutations (e.g., Q67H/K70R, M66I) have emerged in clinical trials. While KFA-012 showed some improved activity against Q67H/K70R, the M66I variant remained resistant to both LEN and KFA-012.
  • Future Directions: The authors suggest that these findings provide a "proof-of-concept for the rational development of second-generation CA inhibitors with enhanced barriers to resistance." This implies further optimization and exploration of chemical space around the KFA-012 scaffold or entirely new approaches to overcome resistance. Continued structural and mechanistic studies of emerging resistance mutations will be crucial.

Summary updated

Abstract

Lenacapavir (LEN) is a long-acting, highly potent HIV-1 capsid (CA) inhibitor. The evolution of viral variants under the genetic pressure of LEN identified Q67H, N74D, and Q67H/N74D CA substitutions as the main resistance associated mutations (RAMs). Here, we determined high-resolution structures of CA hexamers containing these RAMs in the absence and presence of LEN. Our findings reveal that the Q67H change induces a conformational switch, which adversely affects the inhibitor binding. In the unliganded protein, the His67 side chain adopts the closed conformation by projecting into the inhibitor binding pocket and thereby creating steric hindrance with respect to LEN. Upon the inhibitor binding, the His67 side chain repositions to the open conformation that closely resembles the Gln67 side chain in the WT protein. We propose that the switch from the closed conformation to the open conformation, which is needed to accommodate LEN, accounts for the reduced inhibitor potency with respect to the Q67H CA variant. The N74D CA change results in the loss of a direct hydrogen bond and in induced electrostatic repulsions between CA and LEN. The double Q67H/N74D substitutions exhibited cumulative effects of respective single amino acid changes. An examination of LEN binding kinetics to CA hexamers revealed that Q67H and N74D CA changes adversely influenced the inhibitor binding affinity (<i>K<sub>D</sub></i>) by primarily affecting the dissociation rate constant (<i>k<sub>off</sub></i>). We used these structural and mechanistic findings to rationally modify LEN. The resulting analog exhibited increased potency against the Q67H/N74D viral variant. Thus, our studies provide a means for the development of second-generation inhibitors with enhanced barriers to resistance. <b>IMPORTANCE</b> LEN is an investigational long-acting agent for future HIV-1 treatment regimens. While ongoing clinical trials have highlighted a largely beneficial profile of LEN for the treatment of HIV-1 infected people with limited therapy options, one notable shortcoming is a relatively low barrier of viral resistance to the inhibitor. Cell culture-based viral breakthrough assays identified N74D, Q67H, and N74D/Q67H capsid changes as the main resistance associated mutations (RAMs). N74D and Q67H capsid substitutions have also emerged in clinical trials in some patients who received subcutaneous LEN. Understanding the structural basis behind viral resistance to LEN is expected to aid in the rational development of improved inhibitors with enhanced barriers to resistance. Here, we report high resolution structures of the main drug resistant capsid variants, which provide mechanistic insight into the viral resistance to LEN. We used these findings to develop an improved inhibitor, which exhibited enhanced activity against the viral Q67H/N74D capsid phenotype compared with that of parental LEN.
BibTeX
@inproceedings{bester2022structural,
  author = {S.M. Bester and Daniel Adu‐Ampratwum and Arun S. Annamalai and Guochao Wei and Lorenzo Briganti and Bridget C. Murphy and Reed Haney and James R. Fuchs and Mamuka Kvaratskhelia},
  title = {{Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir}},
  booktitle = {mBio},
  year = {2022},
  doi = {10.1128/mbio.01804-22},
}
Figure